Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease

Digestion

Volumn 70, Issue 1, 2004, Pages 61-69

  Van Zyl, J ^a   Van Rensburg, C ^b   Vieweg, W ^d   Fischer, R ^c  

^a University Hospital   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c ALTANA PHARMA AG   (Germany)

^d NONE

Author keywords

Gastroesophageal reflux disease; Gastrointestinal symptoms, reflux disease; Pantoprazole; Ranitidine; Safety, pantoprazole

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; PANTOPRAZOLE; PERINDOPRIL; PROTON PUMP INHIBITOR; RANITIDINE; THEOPHYLLINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; EPIGASTRIC PAIN; ERUCTATION; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; URTICARIA; VERTIGO; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OMEPRAZOLE; PLACEBOS; RANITIDINE; SEVERITY OF ILLNESS INDEX; SULFOXIDES; TREATMENT OUTCOME;

EID: 4444260652     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080130     Document Type: Article

References (27)

1. Ollyo JB, Monnier P, Fontolliet C, Savary M: The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3(suppl):3-10.
2. Wienbeck M, Barnert J: Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl 1989;156:7-13.
3. Glise H, Hallerback B, Johansson B: Quality of life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995;208:133-135.
4. Revicki DA, Wood M, Maton PN, Sörensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-258.
5. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO: Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-1630.
6. Kaplan-Machlis B, Spiegler GE, Revicki DA: Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999;33:1032-1036.
7. Jones R: Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol Suppl 1995;211:35-38.
8. Jones RH, Lydeard SE, Hobbs FD, Kenkre JE, Williams EI, Jones SJ, Repper JA, Caldow JL, Dunwoodie WM, Bottomley JM: Dyspepsia in England and Scotland. Gut 1990;31:401-405.
9. Fennerty MB, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas PJ, Leiberman D, Richter JE, Sampliner RE: The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines. Arch Intern Med 1996;156:477-484.
10. Dent J, Jones R, Kahrilas P, Talley NJ: Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-347.
11. van Zyl JH, de K Grundling H, van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, Fischer R, Bethke T: Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: A randomized, double-blind, parallel, and multicentre study. Eur J Gastroenterol Hepatol 2000;12:197-202.
12. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
13. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-1810.
14. Klok RM, Postma MJ, Van Hout BA, Brouvers JR: Meta-analysis: Comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-1245.
15. Yacyshyn BR, Thomson AB: The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002;66:67-78.
16. Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, Mutschler E, Playford R, Spechler SJ, Stanghellini V, Modlin IM: GERD 2003 - a consensus on the way ahead. Digestion 2003;67:111-117.
17. Katz PO: Gastroesophageal reflux disease - state of the art. Rev Gastroenterol Disord 2001;1:128-138.
18. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003;63:101-133.
19. Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERDrelated symptoms. Aliment Pharmacol Ther 2003;18:587-594.
20. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U: 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38:332-340.
21. Cada DJ, Levien T, Baker DE: Pantoprazole. IV. Hosp Pharm 2001;36:846-854.
22. Dettmer A, Vogt R, Sielaff F, Luhmann R, Schneider A, Fischer R: Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998;12:865-872.
23. Kaspari S, Biedermann A, Mey J: Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001;63:163-170.
24. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-665.
25. Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Gatz G, Bohuschke M: Interim analysis of POETrial, the pantoprazole/ omeprazole equivalence trial: Healing of lesions in patients with gastroesophageal reflux disease II/III after 4 weeks of treatment with pantoprazole 40 mg or omeprazole 40 mg once daily (abstract). Gastroenterology 2001;120(suppl):438.
26. Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, Gatz G: Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis: Results of a multinational study. Digestion 2003;67:6-13.
27. Dent J, Watts R, Riley S, Scheikh R, de Groot G, van Oudvorst A, Hatlebakk JG, Haug K, Carlsson R, Dalvag A, Junghard O, Wiklund I: Omeprazole improves quality of life in patients with gastroesophageal reflux disease (abstract). Gastroenterology 1996;110(suppl):94.